Luca Boscolo Bielo is a medical oncology fellow at the European Institute of Oncology and the University of Milan. His proposed project will be conducted at Memorial Sloan Kettering Cancer Center, New York, and will be focused on understanding how tumor clonality may modulate the sensitivity and acquired resistance to targeting ESR1 in metastatic, hormone-receptor-positive breast cancers. The project aims to better stratify patients who are likely to benefit from targeted treatments, unveiling poorly defined mechanisms of resistance to optimize treatment strategies and improve clinical outcomes.

Marianna Palazzo graduated with honors in Medicine from the University of Perugia and has just completed the Hematology residency at the University of Florence. Throughout her training, she has focused on clinical and laboratory aspects of aggressive lymphomas. Since the beginning of 2024, Dr. Palazzo has collaborated with the laboratory of Dr. Margaret Shipp at Dana-Farber Cancer Institute of Boston, where she will continue her work as a postdoctoral researcher. Her awarded project aims to characterize the genetic and microenvironmental signatures of extranodal diffuse large B-cell lymphomas, that have poor outcomes and represent an unmet medical need, with the goal of revealing subtype-specific novel therapeutic targets.

Federica Pecci is a Medical Oncologist from the University of Parma, currently based at Dana-Farber Cancer Institute’s Lowe Center for Thoracic Oncology of Boston. She has focused her research over the past three years on non-small cell lung cancer (NSCLC) harboring genomic alterations of MET and on the identification of biomarkers of response and resistance to immunotherapy in advanced NSCLC. The focus of her project is to characterize the clinicopathologic, genomic and immunophenotypic factors associated with efficacy of chemoimmunotherapy in resectable NSCLCto define biomarkers that can support patient stratification in clinical practice and related tailored therapeutic strategy in the perioperative setting.

Fondazione Gianni Bonadonna (www.fondazionebonadonna.org) was launched to honor and pursue the legacy of Gianni Bonadonna, founding father of modern oncology who developed key new therapies for women with breast cancer and patients with lymphomas. Fondazione Gianni Bonadonna’s mission is to promote therapeutic innovation from the earliest phases of research and support the education of new generations of physician-scientists in oncology.

Prada Group - The Prada Group is socially engaged to contribute to the sustainable development of the communities and stimulate the cultural debate in all its forms of expression. The Group partners with recognized players and international entities to develop educational and training programs, value talent, support scientific research, foster women’s empowerment, and promote local culture and artistic heritage. The Prada Group operates in the luxury sector through the Prada, Miu Miu, Church’s, Car Shoe, Marchesi 1824 and Luna Rossa brands.

European School of Oncology - The European School of Oncology (ESO) is an independent and self-funded non-profit organization, dedicated to high-quality education and training in oncology, to provide patients with equal access to the standard of care. ESO was founded in 1982 by Umberto Veronesi and Laudomia Del Drago, with the mission to reduce the number of cancer deaths due to late diagnosis or inadequate treatment. With the same commitment, ESO today provides extensive and multidisciplinary oncology education programs for the improvement of treatment options for cancer patients.